The results showed that DPP-4 inhibitors were the most prevalent outpatient AD monotherapy followed by metformin, which are in agreement with the findings from the web-based survey of physicians’ prescribing preferences [8] as well as other studies [12]. The gene discussed is DPP4; the disease is Alzheimer disease.